home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

AJPL PHARMA

SHARESHARESHARE
Sales professional in the medical sector and 15 years of experience. We have concentrated our activity in the distribution of refrigerated cabinets, temperature recorders, and can meet all types of needs for the storage of heat-sensitive medicines.
SHARESHARESHARE

RELATED NEWS


The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections. "Fluoroquinolones have risks and benefits that should be considered very carefully," said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation...
WORLDPHARMANEWS.COM
READ MORE

Eli Lilly’s experimental breast cancer drug abemaciclib has been granted a priority review by US regulators for two indications, and is now on track to be filed in Europe later this year. The US Food and Drug Administration will consider the drug’s use as monotherapy for patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who had prior endocrine therapy and chemotherapy for metastatic disease, and also in combination wit...

READ MORE

Robocath, based in Rouen, France, landed European regulatory approval to introduce its R-One robotic catheterization system. The R-One provides interventional cardiologists a way to precisely advance and manipulates catheter-based tools while remaining apart from patients and not exposed to dangerous X-rays. The company believes that the system can improve certain procedures by providing a reliable and accurate use of instruments, without depending on the physician’s ability to provide the...

READ MORE

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As the pandemic plays out, political divisions have unfolded around hydroxychloroquine and reopening economies, for starters. At center stage last week was a House hearing over ousted Biomedical Advanced Research and Development Authority (BARDA) Director Rick Bright’s whistleblower complaint. While...
FIERCEPHARMA
READ MORE

Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies. The German drugmaker has reached an agreement to transfer all rights to its CAR-T technology and development programmes to US biotech company Intrexon in return for a $150 million equity stake in the Maryland-based firm, plus a note for another $25 million in stock. Merck is also giving Intrexon $25 million in cash to help get the CAR-T programmes...

READ MORE

Sophiris Bio has completed its investigation into the death of a patient that halted additional dosing in a trial of its lead candidate topsalysin two months ago, finding its procedure for localized prostate cancer was unlikely to be the cause. Sophiris’ stock was up 30% on the news, after dropping precipitously in June. The company said it has notified regulatory authorities in the U.S. and the U.K., where the open-label phase 2b study is being conducted. Topsalysin, a transmembrane, pore...
CONOR HALE
READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...